While these PTs are distinct within the MedDRA® hierarchy (e.g., Alanine aminotransferase increased belongs to Investigations, whereas Hepatic function abnormal is categorized under Hepatobiliary disorders), they collectively align with the hepatotoxicity profile described in TAF’s prescribing information, which explicitly lists ALT elevation as an adverse reaction. The gene discussed is GPT; the disease is hepatobiliary disorder.